Long-term toxic effects of adjuvant chemotherapy in breast cancer

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 1939-1947

  Azim, Jr ^a   de Azambuja, E ^a   Colozza, M ^b   Bines, J ^c   Piccart, M J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b S MARIA HOSPITAL   (Italy)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adjuvant breast cancer; Cardiac toxicity; Chemotherapy; Cognitive function; Fertility; Long term toxicity

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MODAFINIL; PACLITAXEL; RAZOXANE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; AMENORRHEA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CARDIOTOXICITY; COGNITION; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOXICITY; FERTILITY; HEART DISEASE; HEART FAILURE; HUMAN; LEUKEMIA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY LEUKEMIA; SEXUAL FUNCTION; SIDE EFFECT; SYSTEMIC THERAPY;

EID: 79956131298     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq683     Document Type: Review

References (94)

1. Colozza M, de Azambuja E, Cardoso F et al. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist 2006; 11: 111-125.
2. Berrino F, Gatta G, Sant M, Capocaccia R. The EUROCARE study of survival of cancer patients in Europe: aims, current status, strengths and weaknesses. Eur J Cancer 2001; 37: 673-677.
3. Clegg LX, Li FP, Hankey BF et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002; 162: 1985-1993.
4. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008; 14: 14-24.
5. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
6. Ryberg M, Nielsen D, Skovsgaard T et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3502-3508.
7. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
8. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23: 2900-2902.
9. Zambetti M, Moliterni A, Materazzo C et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001; 19: 37-43.
10. Bonneterre J, Roche H, Kerbrat P et al. Long-term cardiac follow-up in relapsefree patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004; 22: 3070-3079.
11. Ganz PA, Hussey MA, Moinpour CM et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol 2008; 26: 1223-1230.
12. Pinder MC, Duan Z, Goodwin JS et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25: 3808-3815.
13. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699-709.
14. Orditura M, Quaglia F, Morgillo F et al. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). Oncol Rep 2004; 12: 549-556.
15. Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.
16. Batist G, Harris L, Azarnia N et al. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006; 17: 587-595.
17. Chan S, Davidson N, Juozaityte E et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004; 15: 1527-1534.
18. Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-1332.
19. Venturini M, Michelotti A, Del Mastro L et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14: 3112-3120.
20. Swain SM, Whaley FS, Gerber MC et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997; 15: 1333-1340.
21. Marty M, Espie M, Llombart A et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 2006; 17: 614-622.
22. Lopez M, Vici P, Di Lauro K et al. Randomized prospective clinical trial of highdose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998; 16: 86-92.
23. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation 2006; 114: 2474-2481.
24. Tallaj JA, Franco V, Rayburn BK et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 2005; 24: 2196-2201.
25. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48: 2258-2262.
26. Gianni L, Baselga J, Eiermann W et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005; 11: 8715-8721.
27. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313.
28. Jones S, Holmes FA, O'Shaughnessy J et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27: 1177-1183.
29. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-5671.
30. Schaapveld M, Visser O, Louwman MJ et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 2008; 26: 1239-1246.
31. Beadle G, Baade P, Fritschi L. Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers. Ann Oncol 2009; 20: 103-109.
32. Praga C, Bergh J, Bliss J et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005; 23: 4179-4191.
33. Tallman MS, Gray R, Bennett JM et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol 1995; 13: 1557-1563.
34. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003; 21: 1195-1204.
35. Burnell M, Levine MN, Chapman JA et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 2010; 28: 77-82.
36. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400: 233-255.
37. Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007: 453-459.
38. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-3552.
39. Diamandidou E, Buzdar AU, Smith TL et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 1996; 14: 2722-2730.
40. Hershman D, Neugut AI, Jacobson JS et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99: 196-205.
41. Patt DA, Duan Z, Fang S et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 2007; 25: 3871-3876.
42. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
43. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77-78; author reply 79-80.
44. Vardy J. Cognitive function in breast cancer survivors. Cancer Treat Res 2009; 151: 387-419.
45. Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychologic impact of standarddose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20: 485-493.
46. Brezden CB, Phillips KA, Abdolell M et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18: 2695-2701.
47. Bender CM, Paraska KK, Sereika SM et al. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage 2001; 21: 407-424.
48. Falleti MG, Sanfilippo A, Maruff P et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005; 59: 60-70.
49. Schagen SB, Muller MJ, Boogerd W, Van Dam FS. Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective. Clin Breast Cancer 2002; 3 (Suppl 3): S100-S108.
50. Debess J, Riis JO, Pedersen L, Ewertz M. Cognitive function and quality of life after surgery for early breast cancer in North Jutland, Denmark. Acta Oncol 2009; 48: 532-540.
51. Debess J, Riis JO, Engebjerg MC, Ewertz M. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 2010; 121: 91-100.
52. Jenkins V, Shilling V, Deutsch G et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006; 94: 828-834.
53. Schagen SB, Muller MJ, Boogerd W et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006; 98: 1742-1745.
54. Biglia N, Moggio G, Peano E et al. Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med 2010; 7: 1891-1900.
55. Tager FA, McKinley PS, Schnabel FR et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat 2010; 123: 25-34.
56. Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009; 63: 761-767.
57. Fan HG, Park A, Xu W et al. The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 2009; 18: 156-161.
58. Kohli S, Fisher SG, Tra Y et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009; 115: 2605-2616.
59. Mar Fan HG, Clemons M, Xu W et al. A randomised, placebo-controlled, doubleblind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008; 16: 577-583.
60. Vardy J, Wefel JS, Ahles T et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008; 19: 623-629.
61. Tarone RE. Breast cancer trends among young women in the United States. Epidemiology 2006; 17: 588-590.
62. El Saghir NS, Khalil MK, Eid T et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg 2007; 5: 225-233.
63. Fredholm H, Eaker S, Frisell J et al. Breast cancer in young women: poor survival despite intensive treatment. PLoS One 2009; 4: e7695.
64. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
65. Peccatori F, Cinieri S, Orlando L, Bellettini G. Subsequent pregnancy after breast cancer. Recent Results Cancer Res 2008; 178: 57-67.
66. Partridge AH, Gelber S, Peppercorn J et al. Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer 2008; 8: 65-69.
67. Partridge AH, Ruddy KJ. Fertility and adjuvant treatment in young women with breast cancer. Breast 2007; 16 (Suppl 2): S175-S181.
68. Partridge A, Gelber S, Gelber RD et al. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 2007; 43: 1646-1653.
69. Parulekar WR, Day AG, Ottaway JA et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J Clin Oncol 2005; 23: 6002-6008.
70. Petrek JA, Naughton MJ, Case LD et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24: 1045-1051.
71. Goodwin PJ, Ennis M, Pritchard KI et al. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 1999; 17: 120-129.
72. Abusief ME, Missmer SA, Ginsburg ES et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010; 116: 791-798.
73. Gelber S, Coates AS, Goldhirsch A et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 2001; 19: 1671-1675.
74. Velentgas P, Daling JR, Malone KE et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 1999; 85: 2424-2432.
75. Kroman N, Jensen MB, Wohlfahrt J, Ejlertsen B. Pregnancy after treatment of breast cancer-a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol 2008; 47: 545-549.
76. Azim HA Jr, Santoro L, Pavlidis N et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer 2011; 47: 74-83.
77. Langagergaard V, Gislum M, Skriver MV et al. Birth outcome in women with breast cancer. Br J Cancer 2006; 94: 142-146.
78. Dalberg K, Eriksson J, Holmberg L. Birth outcome in women with previously treated breast cancer-a population-based cohort study from Sweden. PLoS Med 2006; 3: e336.
79. Azim HA Jr, Bellettini G, Gelber S, Peccatori FA. Breast-feeding after breast cancer: if you wish, madam. Breast Cancer Res Treat 2009; 114: 7-12.
80. Gorman JR, Usita PM, Madlensky L, Pierce JP. A qualitative investigation of breast cancer survivors' experiences with breastfeeding. J Cancer Surviv 2009; 3: 181-191.
81. Tralins AH. Lactation after conservative breast surgery combined with radiation therapy. Am J Clin Oncol 1995; 18: 40-43.
82. Moran MS, Colasanto JM, Haffty BG et al. Effects of breast-conserving therapy on lactation after pregnancy. Cancer J 2005; 11: 399-403.
83. Azim HA Jr, Bellettini G, Liptrott SJ et al. Breastfeeding in breast cancer survivors: pattern, behaviour and effect on breast cancer outcome. Breast 2010; 19: 527-531.
84. Schultz WC, Van De Wiel HB. Sexuality, intimacy, and gynecological cancer. J Sex Marital Ther 2003; 29 (Suppl 1): 121-128.
85. Hawkins Y, Ussher J, Gilbert E et al. Changes in sexuality and intimacy after the diagnosis and treatment of cancer: the experience of partners in a sexual relationship with a person with cancer. Cancer Nurs 2009; 32: 271-280.
86. Ganz PA, Desmond KA, Belin TR et al. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999; 17: 2371-2380.
87. Yang EJ, Kim SW, Heo CY, Lim JY. Longitudinal changes in sexual problems related to cancer treatment in Korean breast cancer survivors: a prospective cohort study. Support Care Cancer 2010; doi: 10.1007/s00520-010-0885-y.
88. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology 2004; 13: 295-308.
89. Emilee G, Ussher JM, Perz J. Sexuality after breast cancer: a review. Maturitas 2010; 66: 397-407.
90. Hordern AJ, Street AF. Communicating about patient sexuality and intimacy after cancer: mismatched expectations and unmet needs. Med J Aust 2007; 186: 224-227.
91. Hordern AJ, Street AF. Constructions of sexuality and intimacy after cancer: patient and health professional perspectives. Soc Sci Med 2007; 64: 1704-1718.
92. Ganz PA, Rowland JH, Desmond K et al. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998; 16: 501-514.
93. Peccatori FA, Azim HA Jr. Pregnancy in breast cancer survivors: a need for proper counseling. Breast 2009; 18: 337-338.
94. Dinh P, Sotiriou C, Piccart MJ. The evolution of treatment strategies: aiming at the target. Breast 2007; 16 (Suppl 2): S10-S16.